tbuckley/cabot-search huggingface dataset:
Hepatic mitochondrial DNA/Toll‐like receptor 9/MicroRNA‐223 forms a negative feedback loop to limit neutrophil overactivation and acetaminophen hepatotoxicity in mice
Authors: Yong He, Dechun Feng, Man Li, Yanhang Gao, Teresa Ramirez, Haixia Cao, Seung‐Jin Kim, Yang Yang, Yan Cai, Cynthia Ju, Hua Wang, Jun Li, Bin Gao
Journal: Hepatology (2017)

Acetaminophen (APAP) overdose is a leading cause of acute liver failure worldwide, in which mitochondrial DNA (mtDNA) released by damaged hepatocytes activates neutrophils through binding of Toll-like receptor 9 (TLR9), further aggravating liver injury. Here, we demonstrated that mtDNA/TLR9 also activates a negative feedback pathway through induction of microRNA-223 (miR-223) to limit neutrophil overactivation and liver injury. After injection of APAP in mice, levels of miR-223, the most abundant miRNAs in neutrophils, were highly elevated in neutrophils. Disruption of the miR-223 gene exacerbated APAP-induced hepatic neutrophil infiltration, oxidative stress, and injury and enhanced TLR9 ligand-mediated activation of proinflammatory mediators in neutrophils. An additional deletion of the intercellular adhesion molecule 1 (ICAM-1) gene ameliorated APAP-induced neutrophil infiltration and liver injury in miR-223 knockout mice. In vitro experiments revealed that miR-223-deficient neutrophils were more susceptible to TLR9 agonist-mediated induction of proinflammatory mediators and nuclear factor kappa B (NF-κB) signaling, whereas overexpression of miR-223 attenuated these effects in neutrophils. Moreover, inhibition of TLR9 signaling by either treatment with a TLR9 inhibitor or by disruption of TLR9 gene partially, but significantly, suppressed miR-223 expression in neutrophils post-APAP injection. In contrast, activation of TLR9 up-regulated miR-223 expression in neutrophils in vivo and in vitro. Mechanistically, activation of TLR9 up-regulated miR-223 by enhancing NF-κB binding on miR-223 promoter, whereas miR-223 attenuated TLR9/NF-κB-mediated inflammation by targeting IκB kinase α expression. Collectively, up-regulation of miR-223 plays a key role in terminating the acute neutrophilic response and is a therapeutic target for treatment of APAP-induced liver failure. (Hepatology 2017;66:220-234).
Characterization of Distinct Molecular Signatures in Myeloproliferative Diseases with the JAK2V617F Mutation and Wild Type JAK2.
Authors: Benjamin L. Ebert, Ross L. Levine, Martha Wadleigh, Jean-Philippe Brunet, Jennifer L. Pretz, Lambert Buque, Stephanie J. Lee, D. Gary Gilliland, Todd R. Golub
Journal: Blood (2005)
NON-CODING RNAS COMPREHENSIVELY COUNTERACT ADVERSE ARTERIAL REMODELING AND STIFFENING IN TYPE 2 DIABETES
Authors: Uwe Raaz, Isabel Schellinger, Karin Mattern, Lena Mattes, Joshua Spin, Andreas Schuster, Lars Maegdefessel, Gerd Hasenfuss, Philip Tsao
Journal: Journal of the American College of Cardiology (2017)
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK IN STATIN-NAÏVE ASYMPTOMATIC PATIENTS WITH NON-OBSTRUCTIVE CORONARY ARTERY DISEASE DETECTED BY CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY: THE CONFIRM-LT (CORONARY CT ANGIOGRAPHY EVALUATION FOR CLINICAL OUTCOMES: AN INTERNATIONAL MULTICENTER) REGISTRY
Authors: Ashley Beecy, Donghee Han, Bríain Ó. Hartaigh, Khalil Anchouche, Subhi Al'Aref, Heidi Gransar, Ji Hyun Lee, Mahn Won Park, Hadi Mirhedayati Roudsari, Asim Rizvi, Fay Lin, James Min, Jessica M. Peña
Journal: Journal of the American College of Cardiology (2017)
Is symptom improvement in patients with small cell lung cancer (SCLC) associated with clinical response? An analysis using the Patient Symptom Assessment Lung Cancer (PSALC) scale in a randomized trial comparing oral topotecan (OT) with best supportive care (BSC)
Authors: M. E. O'Brien, M. Duh, L. Chen, L. Antras, M. Neary, B. Dharan, R. J. Gralla
Journal: Journal of Clinical Oncology (2007)

7725 Background: SCLC is a highly symptomatic disease with poor survival in prior treated patients. To evaluate the role of chemotherapy, a recent multicenter trial randomized 141 patients with prior treatment to receive either OT + BSC or BSC only. This was the first trial to use a BSC control group in SCLC while evaluating survival, response and symptoms. Survival data were reported (O'Brien et al JCO 2006; median survival of 25.9 weeks on OT + BSC vs 13.9 weeks on BSC, p = 0.01). 51% on OT had “disease control” (partial response [PR] + stable disease [SD]); no patient on BSC was reported to have a major response, although response was not an endpoint for this group. Trials have shown that those with progressive disease have the most symptom worsening, as occurred in this trial. The objective of this analysis is to determine if patients with PR report greater symptom relief than those with SD, in that SD can reflect a more indolent course in some patients while PR is due to treatment effect only. Methods: We used the investigators evaluation of response (PR or SD) and analyzed these groups by the patients’ scoring of their symptoms using the PSALC instrument which evaluates 9 SCLC symptoms, in the 71 patients on the OT + BSC arm. Results: Patients with lower ECOG PS at baseline reported more severe symptoms (higher PSALC score). Mean changes in PSALC score from baseline are shown in the Table and demonstrate an association between tumor response and decrease in symptoms. Conclusions: Patients who achieved a major response on OT treatment reported significantly better symptom control than those whose best response was SD. This indicates that in addition to a survival benefit, treatment with this chemotherapy can aid in symptom control. While the small number of patients limits the strength of the conclusions, this trial represents the largest BSC controlled study in SCLC. No significant financial relationships to disclose. [Table: see text]
ROLE OF CARDIAC COMPUTED TOMOGRAPHYFOR DIAGNOSIS OF INFECTIVE ENDOCARDITIS AND ITS COMPLICATIONS: INSIGHTS FROM MULTI-MODALITY IMAGING
Authors: In-Cheol Kim, Chi Young Shim, In-Jeong Cho, Hyuk-Jae Chang, Geu-Ru Hong, Jong-Won Ha, Namsik Chung, Cardiology Division
Journal: Journal of the American College of Cardiology (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Authors: Kausik K. Ray, Ulf Landmesser, Lawrence A. Leiter, David Kallend, Robert Dufour, Mahir Karakas, Tim Hall, Roland P.T. Troquay, Traci Turner, Frank L.J. Visseren, Peter Wijngaard, R. Scott Wright, John J.P. Kastelein
Journal: New England Journal of Medicine (2017)

In a previous study, a single injection of inclisiran, a chemically synthesized small interfering RNA designed to target PCSK9 messenger RNA, was found to produce sustained reductions in low-density lipoprotein (LDL) cholesterol levels over the course of 84 days in healthy volunteers.We conducted a phase 2, multicenter, double-blind, placebo-controlled, multiple-ascending-dose trial of inclisiran administered as a subcutaneous injection in patients at high risk for cardiovascular disease who had elevated LDL cholesterol levels. Patients were randomly assigned to receive a single dose of placebo or 200, 300, or 500 mg of inclisiran or two doses (at days 1 and 90) of placebo or 100, 200, or 300 mg of inclisiran. The primary end point was the change from baseline in LDL cholesterol level at 180 days. Safety data were available through day 210, and data on LDL cholesterol and proprotein convertase subtilisin-kexin type 9 (PCSK9) levels were available through day 240.A total of 501 patients underwent randomization. Patients who received inclisiran had dose-dependent reductions in PCSK9 and LDL cholesterol levels. At day 180, the least-squares mean reductions in LDL cholesterol levels were 27.9 to 41.9% after a single dose of inclisiran and 35.5 to 52.6% after two doses (P<0.001 for all comparisons vs. placebo). The two-dose 300-mg inclisiran regimen produced the greatest reduction in LDL cholesterol levels: 48% of the patients who received the regimen had an LDL cholesterol level below 50 mg per deciliter (1.3 mmol per liter) at day 180. At day 240, PCSK9 and LDL cholesterol levels remained significantly lower than at baseline in association with all inclisiran regimens. Serious adverse events occurred in 11% of the patients who received inclisiran and in 8% of the patients who received placebo. Injection-site reactions occurred in 5% of the patients who received injections of inclisiran.In our trial, inclisiran was found to lower PCSK9 and LDL cholesterol levels among patients at high cardiovascular risk who had elevated LDL cholesterol levels. (Funded by the Medicines Company; ORION-1 ClinicalTrials.gov number, NCT02597127 .).
Gene expressions of TS and MDR-1 are predictive factors for chemosensitivity and survival in esophageal cancer with fluoropyrimidine-based chemotherapy
Authors: K. Uchida, K. Hayashi, K. Kudo, H. Kuramochi, M. Yamamoto
Journal: Journal of Clinical Oncology (2007)

14120 Background: Fluoropyrimidines are widely used in chemotherapy regimens for esophageal cancer. To test the hypotheses of whether the relative mRNA expression of the enzyme TS, DPD and MDR-1 were associated with response to in esophageal cancer. We investigated the associations reported between intratumoral TS, DPD and MDR-1 gene expressions and the response with 5-FU based chemotherapy for patients with esophageal cancer. Methods: Twenty six pts with esophageal cancer were treated with 5-FU based chemotherapy (14 pts were treated with chemotherapy only, and 12 pts were chemoradiotherapy). mRNA was isolated from frozen tumor specimens, and relative expression levels of each gene/β-actin were measured using a quantitative reverse transcription polymerase chain reaction (RT-PCR) (Taqman®) system. Results: The overall response rate was 50.0%. Each mRNA expression was detectable in 26 patients. TS expressions were significantly lower in the responding tumors compared to the non-responders respectively (P=0.009). There were no significant associations between MDR-1 expression and the response. By setting up a cut-off level for TS and MDR-1 of Median, combining the two gene expression two-dimensionally revealed a relationship with the response (P=0.037). Additionally, MDR-1 expressions were statistically significant predictors of prolonged survival (P=0.0084). Conclusions: These results suggest that intratumoral TS and MDR-1 expressions are prognostic factors for survival after 5-FU based chemotherapy in esophageal cancer. No significant financial relationships to disclose.
ETHNIC DIFFERENCES OF CORONARY ATHEROSCLEROSIS IN COMPUTED TOMOGRAPHY ANGIOGRAPHY AND SUBSEQUENT RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS: THE CONFIRM REGISTRY
Authors: David Sanders, Aaron Jolly, Nathan D. Wong, Heidi Gransar, Mayil Krishnam, James K. Min, Daniel S. Berman
Journal: Journal of the American College of Cardiology (2017)
Immune response triggered by a novel molecular crosstalk of major hallmarks of cancer: Angiogenesis, mismatch repair, and immune pathways.
Authors: Shannon Graver, Stefan Stremitzer, Yu Sunakawa, Winfried Edelmann, Mark Kockx, Manfred Schartl, Stefan J. Scherer, Heinz-Josef Lenz, Massimiliano Mazzone
Journal: Journal of Clinical Oncology (2015)

11054 Background: The development of bevacizumab to inhibit VEGF has resulted in extended PFS, however OS has failed to show significant clinical benefit in a number of cancer types. Recent data however, has shown bevacizumab to prolong OS in a subset of patients with MMR deficient tumors in adjuvant CRC. Methods: Isolated macrophages were treated with tumor-conditioned media from MMR proficient and MMR deficient tumor cells. Furthermore tumor cells were co-cultured with human monocyte-derived macrophages for analysis of phagocytic activity. Treatment regimens in vitro attempted to mimic the clinical setting by inducing DNA damage in tumor cells, and then allowing cells to recover with or without VEGF using bevacizumab treatment for 24 hrs before co-culture or collection of tumor-conditioned media. Results: Gene expression changes in macrophages induced by tumor-conditioned media showed CCL18 to be a bevacizumab regulated gene. MMR deficient tumor cell conditioned media after DNA damage showed a 68% increase in CCL18 expression compared to the untreated control that was not evident in MMR proficient cells. CXCR4 expression may demonstrate negative regulation as MMR proficient tumor cells treated with bevacizumab after DNA damage, promoted a 1.4 fold increase in CXCR4 expression in macrophages with no functional enhancement of macrophage activity detected. The results of this study also showed an increase in the phagocytic activity of macrophages in the presence of bevacizumab that was significantly more apparent in MMR deficient cells and may be attributed to CCL18. DNA damage in MMR deficient cells in addition to bevacizumab treatment reinforced phagocytosis by a further 16.5% (±3.9%) compared the controls. Moreover, after DNA damage MMR deficient cells treated with bevacizumab released a cytokine mix that reduced monocyte migration in a bevacizumab dependent manner, showing a functional response with the combination of MMR deficiency and bevacizumab. Conclusions: CCL18 is a potential marker for the administration of bevacizumab in a clinical setting that is specific to bevacizumab treatment in combination with MMR deficient tumor cells via immune cell modulation.
COST-EFFECTIVENESS ANALYSIS AND QUALITY OF LIFE OF ON-PUMP AND OFF-PUMP STABLE MULTIVESSEL CORONARY ARTERY BYPASS GRAFTING: MASS III TRIAL 5-YEAR FOLLOW-UP
Authors: Thiago Scudeler, Whady Hueb, Patricia Coelho de Soarez, Alessandro G. Campolina, Paulo Rezende, Eduardo Lima, Cibele Larrosa Garzillo, Diogo Freitas Cardoso Freitas, Leandro Costa, Fernando Teiichi Oikawa, Jose Ramires, Roberto Kalil Filho
Journal: Journal of the American College of Cardiology (2017)
ICPM 2013: 22nd World Congress on Psychosomatic Medicine ‘Psychosomatic Assessment and Integrative Care’,12–14 September, 2013, Lisbon, Portugal
Authors: Giovanni Castellini, Edoardo Mannucci, Carolina Lo Sauro, Laura Benni, Lisa Lazzeretti, Claudia Ravaldi, Carlo M. Rotella, Carlo Faravelli, Valdo Ricca, J. Svaldi, D. Caffier, B. Tuschen-Caffier, C. Faravelli, G. Fioravanti, S. Casale, D. Paciello, A. Miraglia Raineri, L. Fei, G. Amunni, F. Rotella, Laura Batstra, Allen Frances, Katharina Meyerbroeker, Mark B. Powers, Anda van Stegeren, Paul M.G. Emmelkamp, Antonio Tundo, Loretta Salvati, Daniela Di Spigno, Luca Cieri, Anita Parena, Roberta Necci, Stefania Sciortino, Eric A. Fertuck, John Keilp, Inkyung Song, Melissa C. Morris, Scott T. Wilson, Beth S. Brodsky, Barbara Stanley, Astrid Pabst, Maggie Schauer, Kirstin Bernhardt, Martina Ruf, Robert Goder, Rotraudt Rosentraeger, Thomas Elbert, Josef Aldenhoff, Mareen Seeck-Hirschner, Valentina Cardi, Carol Kan, Maria Roncero, Amy Harrison, Naima Lounes, Kate Tchanturia, Caroline Meyer, Jenny Roth, Melanie C. Steffens, Nexhmedin Morina, Ulrich Stangier, Idan M. Aderka, Gideon E. Anholt, Anton J.L.M. van Balkom, Johannes H. Smit, Haggai Hermesh, Patricia van Oppen, Thomas N. Wise, Janet Treasure, Matthew P. Herring, Marni L. Jacob, Cynthia Suveg, Rodney K. Dishman, Patrick J. O'Connor, Giovanni A. Fava, Chiara Ruini, Elena Tomba, Satz Mengensatzproduktion, Druck Reinhardt Druck Basel, Druck Reinhardt Druck Basel
Journal: Psychotherapy and Psychosomatics (2011)
Reduced Intensity Compared to High Dose Conditioning for Allotransplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Comparative Clinical Analysis.
Authors: Catherine Flynn, Juliet N. Barker, Jeff S. Miller, John E. Wagner, Todd DeFor, Bruce R. Blazar, Linda J. Burns, Margaret L. MacMillan, Mukta Arora, Daniel Weisdorf
Journal: Blood (2004)
Anti-CD20 Antibody Rituximab and Anti-CD23 Antibody IDEC-152 Induce Apoptosis of Malignant B-Cells in Combination with Chemical Antagonists of XIAP.
Authors: Massimo Mangiola, Kate Welsh, Shinichi Kitada, Irene M. Pedersen, Nuzhat Pathan, Clementia Pinilla, Thomas J. Kipps, John C. Reed
Journal: Blood (2004)
WHITE BLOOD CELL COUNT AND MAJOR ADVERSE CARDIOVASCULAR EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTION IN THE CONTEMPORARY ERA: INSIGHTS FROM THE PARIS STUDY
Authors: Binita Shah, Usman Baber, Mitchell Krucoff, Melissa Aquino, Timothy Henry, C. Michael Gibson, David Moliterno, Philippe Gabriel Steg, Thomas Stuckey, Stuart Pocock, George Dangas, Cono Ariti, Bernhard Witzenbichler, David Cohen, Ioannis Iakovou, Samantha Sartori, Alaide Chieffo, Annapoorna Kini, Antonio Colombo, Giora Weisz, Roxana Mehran
Journal: Journal of the American College of Cardiology (2017)
Angiogenic marker associated with resistance to neoadjuvant chemoradiotherapy in rectal cancer.
Authors: Hanjo Kim, Min Young Lee, Tae Sung Ahn, Jina Yun, Kyoungha Kim, Se Hyung Kim, Hyun Jung Kim, Sang Cheol Lee, Sang-Byung Bae, Chan Kyu Kim, Namsu Lee, Seong Kyu PARK, Kyu Taek Lee, Jong-Ho Won, Dae Sik Hong, Hee Sook Park, Suk-Young Park, Moon Soo Lee, Moo Jun Baek
Journal: Journal of Clinical Oncology (2013)

11030 Background: The ability to achieve pathologic down staging after neoadjuvant chemoradiotherapy (CRT) is correlated with improved survival. However, there is no effective method of predicting which patients will response to neoadjuvant CRT. Neoadjuvant CRT can change the expression of angiogenic factors. However, little is known about its possible changes in response to preoperative CRT. We examined the expression of angiogenic factors in rectal cancer tissues before preoperative CRT and after surgery. Methods: Fifty five patients with locally advanced rectal cancer were studied. All patients were given preoperative CRT of 5040 cGy for 5-6 weeks with concurrent administration of 5-fluorouracil and leucovorin. Surgical resection was performed 6–8 weeks later in all patients. Immunohistochemical staining for angiogenenic markers (vascular endothelial growth factor [VEGF], placenta growth factor [PLGF], hypoxia inducible factor 1α [HIF 1α], stromal cell derived factor [SDF 1α]) were performed on specimens obtained before preoperative CRT and after surgery. A semiquantitative-immunohistochemical score established from the extension and intensity of the angiogenic factors was used for analysis. Results: The positive expression rate of VEGF, PLGF, SDF 1α, and HIF 1α was 56.4% (31/55), 65.5% (36/55), 70.9% (39/55), and 47.3% (26/55), respectively. The expression rate of VEGF, PLGF, SDF 1α, and HIF 1α was increased by 3.6% (2/55), 7.3% (4/55), 30.9% (17/55), and 1.8% (1/55) after neoadjuvant CRT, respectively. Expression of VEGF, PLGF, and HIF 1α protein was downregulated after neoadjuvant CRT in the rectal cancer tissues (P &lt; 0.001, P = 0.001, P = 0.044, respectively). However, SDF 1α was upregulated after neoadjuvant CRT (P &lt; 0.001). And also, upregulated expression of SDF 1α after neoadjuvant CRT was significantly associated with resistance to CRT (P = 0.035). However, SDF 1α showed no correlation with other clinical factors (age, sex, clinical stage). Conclusions: Expression of SDF-1α was increased in the rectal cancer tissue after neoadjuvant CRT, as well as has been associated with CRT resistance. Our data suggests that SDF 1α should be evaluated as new target for antiangiogenic therapy.
NEOINTIMAL PATTERN AND CLINICAL OUTCOME AFTER DRUG-ELUTING STENT IMPLANTATION: COMPARISON BETWEEN FIRST GENERATION AND SECOND GENERATION DRUG-ELUTING STENTS
Authors: Erika Yamamoto, Takumi Higuma, Lei Xing, Yoshiyasu Minami, Krzysztof Bryniarski, Jiannan Dai, Thomas Zanchin, Tomoyo Sugiyama, Zhao Wang, Aaron Aguirre, Hang Lee, Ik-Kyung Jang
Journal: Journal of the American College of Cardiology (2017)
The effect of raloxifene on breast MRI volume in premenopausal women at increased risk for invasive breast cancer
Authors: J. Eng-Wong, C. K. Chow, J. Orzano, D. Venzon, J. Zujewski, J. Yao, S. Prindiville
Journal: Journal of Clinical Oncology (2007)

1518 Background: Breast MRI volume (MRIV) and mammographic density (MD) assess the amount of fibroglandular tissue in the breast. While increased MD is associated with a 4 to 6 fold increase in breast cancer risk, the association between MRIV and breast cancer is unknown. Previous studies have shown that MRIV and MD can be modulated with hormonal interventions. We evaluated the effect of raloxifene on MRIV in premenopausal women at increased risk for breast cancer. We have previously reported that raloxifene did not change MD in this cohort. Raloxifene is indicated for the prevention and treatment of osteoporosis but not for prevention of breast cancer or for use in premenopausal women. Methods: Premenopausal women at increased risk by virtue of: Gail model risk &gt; 1.7% over 5 years; lobular neoplasia, ductal carcinoma in situ, BRCA1/2 mutation positive, or a very strong family history were eligible for this phase II chemoprevention study. MRIs obtained at baseline and after two years on raloxifene 60 mg daily, and one year after discontinuing the drug were evaluated.T1 weighted spoiled gradient-echo MRI with fat suppression was used to determine volume using a semiautomatic method, after visual verification. Median relative change in MRIV was assessed by the Wilcoxon signed rank test. Results: 19 of 30 subjects who started study drug had breast MRI at baseline and after 2 years on raloxifene; median relative change was -16% (range -57 to +25%) (p=0.0004). 17 subjects had MRI at year 2 and one year after stopping drug. No significant change in MRIV was observed after stopping raloxifene, median relative change -9% (p=0.64). Conclusions: MRIV significantly declined while on raloxifene. In contrast no significant change in percent mammographic density in this same cohort was seen. Our findings suggest that MRIV may be a better surrogate biomarker than MD in premenopausal women at risk for breast cancer because of less variation in its measurement. MRIV should be further evaluated as a potential surrogate biomarker in prevention studies. No significant financial relationships to disclose.
LIRAGLUTIDE AND WEIGHT LOSS AMONG PATIENTS WITH ADVANCED HEART FAILURE AND A REDUCED EJECTION FRACTION: INSIGHTS FROM THE FIGHT TRIAL
Authors: Andrew P. Ambrosy, Abhinav Sharma, Steven McNulty, Barry Borlaug, Thomas Cappola, Lauren Cooper, Adam DeVore, Shannon Dunlay, Anu Lala-Trindade, Kenneth Margulies, Robert Mentz, Eric Velazquez
Journal: Journal of the American College of Cardiology (2017)
A Study on the Induction of Mesoderm Differentiation of Mouse Embryonic Stem Cell in Serum Free Culture.
Authors: Takao Suzuki, Masatomo Takahashi, Tsukasa Miyagi, Michiko Irei, Yasushi Shibuya, Masayuki Kato, Yasuyuki Inoue, Mitsuru Koike, Ikuo Miura
Journal: Blood (2006)
FRACTIONAL FLOW RESERVE IS A SENSITIVE BUT NOT A SPECIFIC DETECTOR OF A HIGH RISK PLAQUES
Authors: Amir Ali Ahmadi, Jonathan Leipsic, Kristian Ovrehus, Sara Gaur, Angel Sanz Salvo, Gina LaRocca, Pedro Moreno, Bjarne Norgaard, Jagat Narula
Journal: Journal of the American College of Cardiology (2017)
Clinical Outcome of Cord Blood Transplantation by Age with Units Shipped from Tokyo Cord Blood Bank.
Authors: Tokiko Nagamura-Inoue, Cui Yan, Hideki Kodo, Hideo Mugishima, Michiko Sugo, Kei Takada, Mika Shioya, Masako Hirai, Atsuko Takahashi, Aya Satomi, Mokaku Hoshino, Yoshiyuki Tahara, Shigetaka Asano, Tsuneo Takahashi
Journal: Blood (2004)